NCT06621212 Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML Status RECRUITING Phase PHASE2
NCT06621199 Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML Status RECRUITING Phase PHASE2
NCT06561880 The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation Status RECRUITING Phase PHASE1/PHASE2
NCT06561152 Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML Status RECRUITING Phase PHASE1/PHASE2
NCT06554626 Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL Status RECRUITING Phase PHASE2
NCT06533748 Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma Status RECRUITING Phase PHASE2
NCT06520176 Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients Status RECRUITING Phase PHASE3
NCT06520163 Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma Status RECRUITING Phase PHASE3
NCT06504459 Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML Status RECRUITING Phase PHASE2
NCT06504199 Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT06497062 Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT06474663 A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias Status WITHDRAWN Phase PHASE1
NCT06451861 Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML Status RECRUITING Phase PHASE2
NCT06434662 Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML Status RECRUITING Phase PHASE2
NCT06429098 Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML Status RECRUITING Phase PHASE2
NCT06390319 Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) Status RECRUITING Phase PHASE2
NCT06387121 Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL Status RECRUITING Phase PHASE2
NCT06377540 MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma Status RECRUITING Phase PHASE2
NCT06376162 Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia Status RECRUITING Phase PHASE1
NCT06361329 Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL Status RECRUITING Phase PHASE3